TNFRSF17 and plasma cell myeloma: In CYAD-211, a miRNA-based shRNA approach was used to silence the mRNA coding for the CD3ζ component of the TCR, co-expressed with an anti-BCMA CAR in the CYAD-211 product, which was evaluated in the phase I IMMUNICY-1 trial (NCT04613557) for the treatment of patients with r/r multiple myeloma.